What is the primary purpose of this 10-Q filing?

The primary purpose of this 10-Q filing is to provide the U.S. Securities and Exchange Commission (SEC) and investors with a quarterly update on Johnson & Johnson's financial performance, condition, and significant business developments for the period ending June 28, 1997.

What key financial metrics can I expect to find in the full 10-Q report?

The full 10-Q report typically contains unaudited interim financial statements, including the balance sheet, statement of operations, and statement of cash flows. It also includes Management's Discussion and Analysis of Financial Condition and Results of Operations, which provides commentary on the company's performance, trends, and future outlook.

Given the limited information provided, what are the general business areas of Johnson & Johnson?

Based on general knowledge of Johnson & Johnson during that period and its typical business structure, the company operates across major segments of the healthcare industry, which historically include Pharmaceuticals, Medical Devices & Diagnostics, and Consumer Health products.

Where can I find the complete Johnson & Johnson 10-Q filing from August 1997?

To access the complete filing, you would typically need to search the SEC's EDGAR (Electronic Data Gathering, Analysis, and Retrieval) database using the company name (JOHNSON & JOHNSON) and the filing type (10-Q) along with the relevant filing date or period.

JNJ 10-Q Quarterly Report Q2 FY1997 — Revenue, Net Income, EPS

Summary

Johnson & Johnson's 10-Q filing for the period ending June 28, 1997, indicates a company operating within the healthcare sector, likely encompassing pharmaceuticals, medical devices, and consumer health products. While specific financial figures for revenue, profit, or significant balance sheet changes are not detailed in the provided excerpt, the filing's existence signals adherence to regulatory reporting standards. Investors should note that this filing represents a snapshot in time during the late 1990s, a period of substantial growth and consolidation in the healthcare industry. For a comprehensive understanding, investors would need to consult the full filing to analyze key financial metrics, management's discussion and analysis of financial condition and results of operations, and any disclosed risks or significant events. The core business segments of JNJ have historically been a source of consistent performance, and understanding the performance drivers for each segment in this quarter would be crucial for assessing the company's ongoing health and future prospects.

Key Highlights

1The filing is a 10-Q report for Johnson & Johnson (JNJ) for the period ending June 28, 1997.
2The report was filed on August 7, 1997.
3This filing provides a quarterly update on the company's financial performance and condition.
4Johnson & Johnson operates in the healthcare industry, likely across pharmaceuticals, medical devices, and consumer health products.
5The provided text is a directory listing, not the full financial statements, requiring further access to the actual filing for detailed financial analysis.
6The filing format indicates adherence to SEC reporting requirements for publicly traded companies.
7Investors can use this filing to assess the company's operational performance and financial health during the second quarter of 1997.

JOHNSON & JOHNSON Quarterly Report for Q2 Ended Jun 29, 1997

Summary

Key Highlights

Frequently Asked Questions